Category: JCN Newswire

Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer’s Disease Research, at the AD/PD 2023 Annual Meeting

TOKYO, Mar 23, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of

More